Home Stock

Stock Research: TherapeuticsMD

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

TherapeuticsMD

NSQ:TXMD US88338N1072
46
  • Value
    89
  • Growth
    57
  • Safety
    Safety
    48
  • Combined
    63
  • Sentiment
    20
  • 360° View
    360° View
    46
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

TherapeuticsMD, Inc. is a pharmaceutical royalty company. It operates in the pharmaceutical industry and collects royalties from its licensees, including products like IMVEXXY, BIJUVA, and ANNOVERA. In the last fiscal year, the company had a market cap of $14 million and a revenue of $2 million.

more

ANALYSIS: With an Obermatt 360° View of 30 (better than 30% compared with alternatives), overall professional sentiment and financial characteristics for the stock TherapeuticsMD are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for TherapeuticsMD. The consolidated Value Rank has an attractive rank of 87, which means that the share price of TherapeuticsMD is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 87% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 51, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 13. Professional investors are more confident in 87% other stocks. Worryingly, the company has risky financing, with a Safety rank of 42. This means 58% of comparable companies have a safer financing structure than TherapeuticsMD. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Price vs. Book (P/B)
Country USA
Industry Pharmaceuticals
Size X-Small
Website therapeuticsmd.com
Index
TherapeuticsMD stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
89 45 57 83
Growth
57 1 7 25
Safety
Safety
48 80 1 26
Sentiment
20 6 47 47
360° View
360° View
46 11 12 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 1 1 58
Opinions Change
50 50 50 50
Pro Holdings
n/a 1 85 78
Market Pulse
1 3 5 10
Sentiment
20 6 47 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
89 45 57 83
Growth
57 1 7 25
Safety Safety
48 80 1 26
Combined
63 20 8 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
34 17 26 82
Price vs. Earnings (P/E)
77 77 90 46
Price vs. Book (P/B)
92 83 61 94
Dividend Yield
1 1 1 1
Value
89 45 57 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
85 4 100 71
Profit Growth
51 1 16 51
Capital Growth
37 26 3 41
Stock Returns
49 11 15 7
Growth
57 1 7 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
51 100 100 5
Refinancing
86 76 37 81
Liquidity
20 8 31 29
Safety Safety
48 80 1 26

Similar Stocks

Discover high‑ranked alternatives to TherapeuticsMD and broaden your portfolio horizons.

Toll Brothers

NYQ:TOL
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Regeneron Pharmaceuticals

NSQ:REGN
Country: USA
Industry: Biotechnology
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews